budesonide (Rhinocort, Pulmicort, Turbuhaler, Flexhaler, Entocort EC, Uceris, Cortiment, Eohilia)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradenames: Rhinocort, Pulmicort, Turbuhaler, Flexhaler, Pulmicort Respules (solution for nebulizer), Entocort EC, Eohilia

Indications

Contraindications

Caution:

pregnancy category = c

safety in lactation = -

Dosage

  • nasal spray: 2 sprays BID or 4 sprays QD.
  • inhaler:
    • 1-2 puffs BID, max: 4 puffs BID (2 puffs BID for children) 360 ug/day is adult dose
    • Turbuhaler: 200 ug/actuation; 160 ug from the mouth piece. 200 doses/inhaler
    • Flexhaler: 90 & 180 ug/actuation[5] {contains lactose}
  • nebulizer BID, 0.25 & 0.5 mg/mL amps
  • oral: 9 mg PO QAM
    • budesonide MMX (Cortiment, Uceris): once daily colonic delivery system for ulterative colitis; 9 mg PO QAM[9]
  • no intravenous formulation

Capsules: 3 mg

Pharmacokinetics

elimination via liver

Adverse effects

Drug interactions

Laboratory

Notes

More general terms

Additional terms

Component of

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 743
  3. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  4. 4.0 4.1 Journal Watch 20(9):70, 2000 Day et al J Allergy Clin Immunol 105:489, 2000
  5. 5.0 5.1 5.2 Prescriber's Letter 14(6): 2007 Pulmicort Flexhaler (Budesonide Inhalation Powder) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=2306209&pb=PRL (subscription needed) http://www.prescribersletter.com
  6. Prescriber's Letter 17(7): 2010 Clarithromycin Interaction with Salmeterol and Inhaled Corticosteroids Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260701&pb=PRL (subscription needed) http://www.prescribersletter.com
  7. Prescriber's Letter 20(3): 2013 Treatments for Ulcerative Colitis Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=290303&pb=PRL (subscription needed) http://www.prescribersletter.com
  8. 8.0 8.1 Deprecated Reference
  9. 9.0 9.1 Hoy SM. Budesonide MMX: a review of its use in patients with mild to moderate ulcerative colitis. Drugs. 2015 May;75(8):879-86. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25920500
  10. 10.0 10.1 Brooks M FDA OKs First Oral Agent for Eosinophilic Esophagitis. Medscape. Feb 12, 2024 https://www.medscape.com/viewarticle/fda-oks-first-oral-agent-eosinophilic-esophagitis-2024a100031d

Database